News | November 28, 2024
Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
The product will be marketed by Dr. Reddy's
The product will be marketed by Dr. Reddy's
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
ORACEA is a trademark of Galderma Holdings, S.A.
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)